Brand Name :
Bumex, Burinex
Synonyms :
bumetanide
Class :
Diuretics, Loop
Dosage Forms & Strengths
Injectable solution
0.25mg/mL
Tablet
0.5mg
1mg
2mg
0.5 - 2
mg
Orally
once a day
; may be repeated every 4-5 hours for up to 2 doses; maximum daily dose is 10 mg
IM- 0.5-1 mg intramuscular once; may be repeated every 2-3 hours for up to 2 doses; maximum daily dose is 10 mg.
IV- 1 mg intravenous at first, then 0.5-2 mg/hr
off-label:
1
mg
Intravenous (IV)
loading dose, followed by 0.5-2 mg/day oral divided every 12 hours.
Safety and efficacy not established.
Refer to adult dosing.
NSAIDs may diminish the diuretic effect of loop diuretics
NSAIDs may diminish the diuretic effect of loop diuretics
NSAIDs may diminish the diuretic effect of loop diuretics
NSAIDs may diminish the diuretic effect of loop diuretics
NSAIDs may diminish the diuretic effect of loop diuretics
may decrease the diuretic effect of nonsteroidal anti-inflammatory agents
may have an increased risk of rhabdomyolysis & myoglobinuria when combined with bumetanide
arsenic trioxide: they may enhance the hypotensive effect of loop diuretics
may increase the hypotensive effect
opioid agonists increase the toxicity of diuretics
opioid agonists increase the toxicity of diuretics
amikacin liposome (oral inhalation)
they decrease the nephrotoxicity of liposomal amikacin oral inhalation
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
Loop Diuretics may increase the hypotensive effect of antihypertensive Agents
loop Diuretics may reduce the neuromuscular blocking effect of neuromuscular-Blocking Agents.
loop Diuretics may reduce the neuromuscular blocking effect of neuromuscular-Blocking Agents.
loop Diuretics may reduce the neuromuscular blocking effect of neuromuscular-Blocking Agents.
loop Diuretics may reduce the neuromuscular blocking effect of neuromuscular-Blocking Agents.
loop Diuretics may reduce the neuromuscular blocking effect of neuromuscular-Blocking Agents.
it increases the hypotensive effect of angiotensin II receptor blockers
it increases the hypotensive effect of angiotensin II receptor blockers
it increases the hypotensive effect of angiotensin II receptor blockers
it increases the hypotensive effect of angiotensin II receptor blockers
it increases the hypotensive effect of angiotensin II receptor blockers
may diminish the diuretic effect of loop diuretics
may diminish the diuretic effect of loop diuretics
may diminish the diuretic effect of loop diuretics
may diminish the diuretic effect of loop diuretics
may diminish the diuretic effect of loop diuretics
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the hypotensive effect of antihypertensive agents
may enhance the hypotensive effect of antihypertensive agents
may enhance the hypotensive effect of antihypertensive agents
may enhance the hypotensive effect of antihypertensive agents
may enhance the hypotensive effect of antihypertensive agents
loop diuretics may increase the risk of adverse effect of aminoglycosides
loop diuretics may increase the risk of adverse effect of aminoglycosides
loop diuretics may increase the risk of adverse effect of aminoglycosides
loop diuretics may increase the risk of adverse effect of aminoglycosides
loop diuretics may increase the risk of adverse effect of aminoglycosides
may enhance the hypotensive effect of angiotensin II receptor antagonist
may enhance the hypotensive effect of angiotensin II receptor antagonist
may enhance the hypotensive effect of angiotensin II receptor antagonist
may enhance the hypotensive effect of angiotensin II receptor antagonist
may enhance the hypotensive effect of angiotensin II receptor antagonist
may increase the risk of adverse effect of cardiac glycosides
may increase the risk of adverse effect of cardiac glycosides
may increase the risk of adverse effect of cardiac glycosides
may diminish the neuromuscular-blocking effect of neuromuscular blocking agents
may diminish the neuromuscular-blocking effect of neuromuscular blocking agents
may diminish the neuromuscular-blocking effect of neuromuscular blocking agents
may diminish the neuromuscular-blocking effect of neuromuscular blocking agents
may diminish the neuromuscular-blocking effect of neuromuscular blocking agents
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
may increase the hypokalemic effect of beta2-agonists
May have an increased nephrotoxic effect when combined with Iodinated Agents
May have an increased nephrotoxic effect when combined with Iodinated Agents
May have an increased nephrotoxic effect when combined with Iodinated Agents
May have an increased nephrotoxic effect when combined with Iodinated Agents
It may enhance the effects when combined with maitake by pharmacodynamic synergism
They may diminish the absorption when combined with bile acid sequestrants
It may enhance toxicity when combined with beclomethasone, inhaled by enhancing elimination
loop diuretics: they may increase the hypotensive effect when combined with antihypertensive drugs
loop diuretics: they may increase the hypotensive effect when combined with antihypertensive drugs
loop diuretics: they may increase the hypotensive effect when combined with antihypertensive drugs
may have an increased adverse/toxic effect when combined with aminoglycosides
neomycin/polymyxin B/bacitracin topical
may have an increased adverse/toxic effect when combined with aminoglycosides
loop Diuretics may increase the hypokalemic effect of dichlorphenamide
it May diminish the therapeutic effect of Loop Diuretics
it May diminish the therapeutic effect of Loop Diuretics
it May diminish the therapeutic effect of Loop Diuretics
it May diminish the therapeutic effect of Loop Diuretics
it May diminish the therapeutic effect of Loop Diuretics
loop Diuretics may enhance the hypokalemic effect of topiramate
may decrease the serum potassium levels
insulin degludec/insulin aspart
may decrease the effect of each other
empagliflozin increases the effect of hypotension of loop diuretics
may increase the hypokalemic effect of corticosteroids
loop diuretics may increase the risk of adverse effect of allopurinol
may reduce the rate of absorption of loop diuretics
may reduce the effect of loop diuretics
may reduce the effect of loop diuretics
may reduce the effect of loop diuretics
may reduce the effect of loop diuretics
may reduce the effect of loop diuretics
may increase the hypotensive effect of calcium channel blockers
may increase the hypotensive effect of antihypertensive agents
may increase the hypotensive effect of angiotensin receptor II blockers
may increase the hypokalemic effect of beta2 agonists
may increase the hypokalemic effect of beta2 agonists
may diminish the therapeutic effect of salicylates
may have an increased nephrotoxic effect when combined with iodinated agents
may have an increased nephrotoxic effect when combined with iodinated agents
may have an increased nephrotoxic effect when combined with iodinated agents
may have an increased nephrotoxic effect when combined with iodinated agents
may have an increased hypokalemic effect when combined with loop diuretics
may have an increased hypokalemic effect when combined with loop diuretics